

Zydus receives final approval from the USFDA for Candesartan Cilexetil Tablets

Ahmedabad, 24 August 2017

Zydus Cadila has received the final approval from the USFDA to market Candesartan Cilexetil Tablets USP 4 mg, 8 mg, 16 mg, and 32 mg. The drug is used to treat high blood pressure (hypertension) in adults and will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
